Dr. Muhunthan Thillai

Dr. Muhunthan Thillai is a consultant chest physician and entrepreneur of Sri Lankan Tamil heritage, born in Sri Lanka and raised in the UK from the age of two. He trained as a doctor, earned a PhD in molecular immunology and proteomics from Imperial College London, and was appointed as a consultant physician and Director of Interstitial Lung Diseases at Royal Papworth and Addenbrooke's Hospitals in Cambridge. He is also an Honorary Associate Professor at the University of East Anglia.

In 2018, Muhunthan co-founded Qureight alongside Dr. Alessandro Ruggiero after recognising that complex clinical datasets were being underutilised in drug development. Qureight emerged from the Accelerate Cambridge programme at Cambridge Judge Business School and builds an AI-powered cloud platform that curates imaging and biomarker data from clinical trials, helping pharmaceutical companies accelerate drug discovery for lung and heart diseases.

Qureight has raised over $11 million across multiple funding rounds, including a $6.8 million Series A, and counts biopharma giants Roche, Galapagos and Takeda among its platform users. The company has expanded into international partnerships, including a collaboration with King Faisal Specialist Hospital in Saudi Arabia and a deployment with Oslo-based Calluna Pharma. Muhunthan continues to practise as a hospital consultant while leading Qureight's commercial and scientific growth.